Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Ifetroban

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Ifetroban
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • 3-[2-({(1S,2R,3S)-3-[4-(Pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]hept-2-yl}methyl)phenyl]propanoic acid
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC25H32N2O5
Molar mass440.540 g·mol−1
3D model (JSmol)
  • O=C(NCCCCC)c1nc(oc1)[C@@H]4C2O[C@@H](CC2)[C@@H]4Cc3ccccc3CCC(=O)O

Ifetroban is a potent and selectivethromboxane receptor antagonist.[1] It has been studied in animal models for the treatment ofcancer metastasis,[2]myocardial ischemia,hypertension,stroke,thrombosis,cardiomyopathy,[3] and for its effects onplatelets.[4][5] Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis,[6] cardiovascular disease,[7] aspirin exacerbated respiratory disease,[8][9][10] systemic sclerosis,[11] andDuchenne muscular dystrophy.[12]

Synthesis

[edit]
Ifetroban synthesis[13][full citation needed]

References

[edit]
  1. ^Rosenfeld L, Grover GJ, Stier CT (2006)."Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist".Cardiovascular Drug Reviews.19 (2):97–115.doi:10.1111/j.1527-3466.2001.tb00058.x.PMID 11484065.
  2. ^Werfel TA, Hicks DJ, Rahman B, Bendeman WE, Duvernay MT, Maeng JG, et al. (December 2020)."Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study".Molecular Cancer Therapeutics.19 (12):2454–2464.doi:10.1158/1535-7163.MCT-19-1106.PMID 33033174.S2CID 222237252.
  3. ^West JD, Voss BM, Pavliv L, de Caestecker M, Hemnes AR, Carrier EJ (June 2016)."Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload".Pulmonary Circulation.6 (2):211–223.doi:10.1086/686140.PMC 4869926.PMID 27252848.
  4. ^Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH (August 2000)."Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans"(PDF).Drug Metabolism and Disposition.28 (8):973–980.PMID 10901709.
  5. ^West JD, Galindo CL, Kim K, Shin JJ, Atkinson JB, Macias-Perez I, et al. (November 2019)."Antagonism of the Thromboxane-Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy".Journal of the American Heart Association.8 (21) e011902.doi:10.1161/JAHA.118.011902.PMC 6898850.PMID 31662020.
  6. ^Clinical trial numberNCT03694249 for "A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence" atClinicalTrials.gov
  7. ^Clinical trial numberNCT03962855 for "The Thromboxane Receptor Antagonist to Blunt the Effects of Non-Platelet Thromboxane Generation and Improve Endothelial Cell Function (TRAP) Trial" atClinicalTrials.gov
  8. ^Clinical trial numberNCT02216357 for "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease" atClinicalTrials.gov
  9. ^Clinical trial numberNCT03326063 for "Therapeutic Control of Aspirin-Exacerbated Respiratory Disease" atClinicalTrials.gov
  10. ^Clinical trial numberNCT03028350 for "A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)" atClinicalTrials.gov
  11. ^Clinical trial numberNCT02682511 for "A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH) " atClinicalTrials.gov
  12. ^Clinical trial numberNCT03340675 for "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy " atClinicalTrials.gov
  13. ^Drugs Future (c.f. Lednicer book 6)
Receptor
(ligands)
DP (D2)Tooltip Prostaglandin D2 receptor
DP1Tooltip Prostaglandin D2 receptor 1
DP2Tooltip Prostaglandin D2 receptor 2
EP (E2)Tooltip Prostaglandin E2 receptor
EP1Tooltip Prostaglandin EP1 receptor
EP2Tooltip Prostaglandin EP2 receptor
EP3Tooltip Prostaglandin EP3 receptor
EP4Tooltip Prostaglandin EP4 receptor
Unsorted
FP (F2α)Tooltip Prostaglandin F receptor
IP (I2)Tooltip Prostacyclin receptor
TP (TXA2)Tooltip Thromboxane receptor
Unsorted
Enzyme
(inhibitors)
COX
(PTGS)
PGD2STooltip Prostaglandin D synthase
PGESTooltip Prostaglandin E synthase
PGFSTooltip Prostaglandin F synthase
PGI2STooltip Prostacyclin synthase
TXASTooltip Thromboxane A synthase
Others
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ifetroban&oldid=1330968368"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp